首页> 美国卫生研究院文献>BMJ Open >Efficacy and safety of 4 weeks treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

【2h】

Efficacy and safety of 4 weeks treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

机译：安慰剂对照随机试验：在吸入器中每天一次使用氟替卡松糠酸酯/维兰特罗联合治疗4星期的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundFluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β2 agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma.

机译：背景糠酸氟替卡松/维兰特罗（FF / VI）是一种新型的每日一次（OD）吸入性皮质类固醇/长效β2激动剂组合，正在开发中用于治疗慢性阻塞性肺疾病（COPD）和哮喘。

著录项

期刊名称 BMJ Open
作者
J Lötvall; P S Bakke; L Bjermer; S Steinshamn; C Scott-Wilson; C Crim; L Sanford; B Haumann;
展开▼
作者单位

展开▼
年(卷),期 2012(2),1
年度 2012
页码 e000370
总页数 11
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of 4?weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial [J] . B Haumann, C Crim, C Scott-Wilson, BMJ Open . 2012,第1期

机译：安慰剂对照随机试验：在COPD中每天一次给予单一吸入剂的糠酸氟替卡松/维兰特罗联合治疗4周的疗效和安全性：
2. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial [J] . Nicola C. Day, Subramanya Kumar, Gerard Criner, Respiratory Research . 2020,第1期

机译：单吸入式三重疗法氟酸甲酸氟酸酯/ UMECLIDINIUM / VILANTEROL与COPD患者的氟替辛呋喃/维尔替洛尔和UMECLIDINUIUM / VILANTEROL：从冲击试验中导致心血管安全性
3. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [J] . Siler Thomas M., Nagai Atsushi, Scott-Wilson Catherine A., Respiratory medicine . 2017,第期

机译：一次每日氟酸甲酸呋喃/维替醇100/25μg的随机，期III试验与一次每日Vilantolol25μg评估氟酮源于COPD患者组合的氟酮源性肺功能的贡献
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Efficacy of the Chinese herbal formula CUF2 in the treatment of childhood asthma: Animal experiment, in vitro study and randomized, double-blinded, placebo-controlled clinical trial. [D] . Wong, Yeuk Oi. 2006

机译：中药配方CUF2在治疗儿童哮喘中的功效：动物实验，体外研究以及随机，双盲，安慰剂对照的临床试验。
6. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions [O] . Arnaud Bourdin, Gerard Criner, Gilles Devouassoux, 2021

机译：通知COPD治疗的途径（影响试验）单吸入器三重治疗（氟胺呋喃/ UmeClidinium / Vilanterol）与COPD患者的氟替辛呋喃/维尔替洛尔和Umeclidinium / Vilantolol：分析西欧和北美地区
7. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial [O] . Lotvall J, Bakke Per S., Bjermer Leif, 2015

机译：安慰剂对照随机试验：在COPD中每天一次给予单一吸入剂的糠酸氟替卡松/维兰特罗联合治疗4周的疗效和安全性：

Efficacy and safety of 4 weeks treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial

摘要

著录项

相似文献

相关主题

期刊订阅